Condition: Relapsed/Refractory Acute Myeloid Leukemia · Sponsor: Nerviano Medical Sciences
The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, including a subset of patients with TP53 mutations. It is anticipated that combination with venetoclax will be further evaluated following a future protocol amendment, once the Recommended Range Dose (RDR) as single agent has been defined.
This description comes directly from the study's public registry record.
Alberto Ocana · +39 0331-581111 · clinicaltrials@nervianoms.com
Always discuss trial participation with your own doctor first.
| City of Hope - Duarte | Duarte, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Aurora, Colorado, United States | Recruiting |
| Medical Oncology Hematology Consultants | Newark, Delaware, United States | Recruiting |
| Blood and Marrow Transplant Group of Georgia | Atlanta, Georgia, United States | Recruiting |
| Mayo Clinic Cancer Center (MCCC) - Rochester | Rochester, Minnesota, United States | Withdrawn |
| Gabrail Cancer Research Center | Canton, Ohio, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06549790